Repligen corp stock.
UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report. November 14, 2023. Our mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide.
Promising Performance: Repligen Corp (RGEN) Stock Shows Potential for Strong Growth in 2023. On November 1, 2023, Repligen Corp (RGEN) stock had a promising performance based on the information provided. According to the data from CNN Money, the 13 analysts offering 12-month price forecasts for RGEN had a median target …... Stock quotes by finanzen.net · Home · Stocks · Repligen-stock · News for Repligen Repligen. News for Repligen Corp. GlobeNewswire 20d. UPDATE – Repligen ...With Repligen stock trading at $164.94 per share, the total value of Repligen stock (market capitalization) is $9.21B. Repligen stock was originally listed at a price of …NASDAQ does not use this value to determine compliance with the listing requirements. Repligen Corporation Common Stock (RGEN) Stock Quotes - Nasdaq offers stock quotes & market activity data for ...
Q3 2023 Repligen Corp Earnings Call finance.yahoo.com - November 1 at 10:15 AM. sfgate.com logo, Repligen: Q3 Earnings Snapshot sfgate.com - October 31 at 11 ...The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, …
The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Repligen Corp. shares valued at $557,328 were sold by Gebski Christine on Nov 10. At $147.13 per share, Gebski Christine sold 3,788 shares.Repligen Corp’s ( RGEN) price is currently down 4.66% so far this month. During the month of March, Repligen Corp’s stock price has reached a high of $189.87 and a low of $160.14. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 37.23%.
View the latest Repligen Corp. (RGEN) stock price, news, historical charts, analyst ratings and financial information from WSJ.A high-level overview of Repligen Corporation (RGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Repligen Corp’s trailing 12-month revenue is $801.5 million with a 23.2% net profit margin. Year-over-year quarterly sales growth most recently was 0.2%. Analysts expect adjusted earnings to reach $2.678 per share for the current fiscal year. Repligen Corp does not currently pay a dividend. How We Compare DexCom, Inc. and Repligen Corp Stock ...Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.54% in the past year. Currently, Repligen Corp’s price-earnings ratio is 72.6. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.Repligen Corp’s Stock Price as of Market Close. As of March 03, 2023, 4:00 PM CST, Repligen Corp’s stock price was $188.00. Repligen Corp is up 4.17% from its previous closing price of $180.48. During the last market session, Repligen Corp’s stock traded between $171.57 and $184.29.
Apr 28, 2023 · Repligen Corp’s Stock Price as of Market Close. As of April 28, 2023, 4:00 PM CST, Repligen Corp’s stock price was $151.63. Repligen Corp is up 4.46% from its previous closing price of $145.15. During the last market session, Repligen Corp’s stock traded between $144.20 and $149.36.
Jul 21, 2023 · Repligen Corp’s ( RGEN) price is currently up 23.95% so far this month. During the month of July, Repligen Corp’s stock price has reached a high of $177.18 and a low of $134.64. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $134.64. Year to date, Repligen Corp’s stock is down 33.79%.
Oct 9, 2023 · With its stock down 4.8% over the past month, it is easy to disregard Repligen (NASDAQ:RGEN). However, stock prices are usually driven by a company’s financials over the long term, which in this ... Repligen ( NASDAQ: RGEN) is owned by 101.54% institutional shareholders, 37.70% Repligen insiders, and 0.00% retail investors. Bvf Partners L P is the largest individual Repligen shareholder, owning 11.06M shares representing 19.81% of the company. Bvf Partners L P's Repligen shares are currently valued at $1.76B.Find the latest Repligen Corporation (RGEN) stock quote, history, news and other vital information to help you with your stock trading and investing.Stock Price Forecast The 13 analysts offering 12-month price forecasts for Repligen Corp have a median target of 170.00, with a high estimate of 210.00 and a low estimate of 148.00.Sep 29, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.8. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.54% in the past year. Currently, Repligen Corp’s price-earnings ratio is 72.6. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.
Discover historical prices for RGEN stock on Yahoo Finance. View daily, weekly or monthly format back to when Repligen Corporation stock was issued.305.46%. Get the latest Repligen Corp (RGEN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Repligen Corp stock has a Growth Score of 82, Estimate Revisions Score of 38 and Quality Score of 71. Comparing Abbott Laboratories and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 7.08% in the past year. Currently, Repligen Corp’s price-earnings ratio is 78.5. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 5.92% in the past year. Currently, Repligen Corp’s price-earnings ratio is 58.8. Repligen Corp’s trailing 12-month revenue is $801.3 million with a 19.9% net profit margin. Year-over-year quarterly sales growth most recently was 12.6%.Repligen Q3 Results Top Estimates; Boosts FY23 Earnings Outlook. (RTTNews) - Life sciences company Repligen Corp. (RGEN) announced Tuesday third-quarter net income of $18.17 million or $0.32 per ...Phone 1 781 250-0111. Industry Biotechnology. Sector Health Care/Life Sciences. Fiscal Year-end 12/2023. Revenue €801.54M. Net Income €185.96M. 2022 Sales Growth 19.54%. Employees 2,025.
Repligen Corp stock has a Value Score of 5, Momentum Score of 54 and Estimate Revisions Score of 37. Comparing Agiliti Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk ...... shares relative to the market in the next few months. In addition, Repligen Corporation has a VGM Score of F (this is a weighted average of the individual ...
CI. Repligen Insider Sold Shares Worth $557,328, According to a Recent SEC Filing. Nov. 13. MT. Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating. Nov. 07. MT. CORRECTION : RBC Trims Price Target on Regeneron Pharmaceuticals to $837 From $847, Keeps Sector Perform Rating. Nov. 03.Get the latest Repligen Corporation (RGEN) stock news and headlines to help you in your trading and investing decisions. Mar 27, 2023 · During the month of March, Repligen Corp’s stock price has reached a high of $189.87 and a low of $157.11. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 36.92%. Complete Repligen Corp. stock information by Barron's. View real-time RGEN stock price and news, along with industry-best analysis.Complete Repligen Corp. stock information by Barron's. View real-time RGEN stock price and news, along with industry-best analysis.Repligen Corp stock has a Value Score of 4, Growth Score of 82 and Estimate Revisions Score of 38. Comparing Avantor Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …Listed in 1986. repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process ...Sep 22, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. Repligen Corp stock has a Value Score of 5, Growth Score of 82 and Momentum Score of 69. Comparing AmerisourceBergen Corp. and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well …Repligen Corp’s ( RGEN) price is currently down 7.18% so far this month. During the month of September, Repligen Corp’s stock price has reached a high of $179.27 and a low of $159.54. Over the last year, Repligen Corp has hit prices as high as $235.06 and as low as $134.64. Year to date, Repligen Corp’s stock is down 39.05%.
Repligen Corp’s ( RGEN) price is currently down 11.17% so far this month. During the month of April, Repligen Corp’s stock price has reached a high of $182.42 and a low of $149.02. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 43.53%.
Repligen Corp., the recipient of this investment, is a global life sciences company specializing in providing bioprocessing technologies and solutions used in manufacturing biological drugs. ... While Repligen’s stock opened at $156.63 on Friday, the company had a market capitalization of $8.72 billion, with a beta of 1.08, and PE ratio of …
NASDAQ does not use this value to determine compliance with the listing requirements. Repligen Corporation Common Stock (RGEN) Stock Quotes - Nasdaq offers stock quotes & market activity data for ...Dec 1, 2023 · Repligen Corp stock has a Growth Score of 82, Estimate Revisions Score of 35 and Quality Score of 70. Comparing Adapthealth Corp and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. 4 thg 4, 2016 ... Once you've won approval for a biologic, or biosimilar, manufactured at a particular facility, you can't just switch to another without jumping ...With its stock down 4.8% over the past month, it is easy to disregard Repligen (NASDAQ:RGEN). However, stock prices are usually driven by a company’s financials over the long term, which in this ...RGN:MUN Munich Stock Exchange; RGN:STU Stuttgart Stock Exchange; RGEN:DEU German Composite; RGN:FRA Frankfurt Stock Exchange; RGN:DUS Dusseldorf Stock Exchange; ... Repligen Corp BUILDING 1, SUITE 100, 41 SEYON STREET WALTHAM 02453 United States USA; Phone +1 (781) 449-9560; Fax +1 (302) …Repligen Corp stock has a Value Score of 5, Growth Score of 82 and Momentum Score of 41. Comparing Premier Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not.... Repligen (RGEN) Frequently Asked Questions. What does Repligen do? Repligen Corp is a global life sciences company. It develops and commercializes innovative ...Repligen Q3 Results Top Estimates; Boosts FY23 Earnings Outlook. (RTTNews) - Life sciences company Repligen Corp. (RGEN) announced Tuesday third-quarter net income of $18.17 million or $0.32 per ...RGN:MUN Munich Stock Exchange; RGN:STU Stuttgart Stock Exchange; RGEN:DEU German Composite; RGN:FRA Frankfurt Stock Exchange; RGN:DUS Dusseldorf Stock Exchange; ... Repligen Corp BUILDING 1, SUITE 100, 41 SEYON STREET WALTHAM 02453 United States USA; Phone +1 (781) 449-9560; Fax +1 (302) …Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. Analysts expect adjusted earnings to reach $1.752 per share for the current fiscal year. Repligen Corp does not currently pay a dividend. How We Compare Steris PLC and Repligen Corp Stock ...The stock’s market cap achieved a total value of $6.67 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Repligen Corp. (NASDAQ:RGEN) is 49.48.
Repligen Corp. analyst ratings, historical stock prices, earnings estimates & actuals. RGEN updated stock price target summary.Aug 3, 2023 · Repligen Corporation is a global company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are 'inspiring advances in bioprocessing' for the customers we serve; primarily biopharmaceutical drug developers and contract ... View the latest Repligen Corp. (RGEN) stock price, news, historical charts, analyst ratings and financial information from WSJ. Instagram:https://instagram. how to purchase otc stocksday trading with a small accountwhat kennedy half dollars are valuablestocks charles schwab Quotes Summary Real-Time Live After-Hours Key Data Bid Price and Ask Price The bid & ask refers to the price that an investor is willing to buy or sell a stock. The bid is the …Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 24.63% in the past year. Currently, Repligen Corp’s price-earnings ratio is 60.3. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. what is the most valuable state quarterleonardo drs stock Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 10.83% in the past year. Currently, Repligen Corp’s price-earnings ratio is 50.0. Repligen Corp’s trailing 12-month revenue is $801.5 million with a 23.2% net profit margin. Year-over-year quarterly sales growth most recently was 0.2%. veng stocks Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.8. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corp stock has a Growth Score of 82, Momentum Score of 48 and Quality Score of 71. Comparing Baxter International Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …RGEN stock, belonging to Repligen Corp, has shown promising performance on October 31, 2023, based on the information provided. The data source for this analysis is CNN Money. According to the 13 analysts, the median target price for Repligen Corp is $195.00. The high estimate is $240.00, while the low estimate stands …